Global CAR T Cell Therapy Market, By Targeted Antigen(CD 19,CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll), Therapeutic Application(Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer), and Geography - Trends, Analysis and Forecast till 2028
- Report code : CMI1102 |
- Industry :
Biotechnology
- Published On : May 2018 |
- Pages : 175 Pages |
- Format :
CAR-T Cell Therapy Market – A Revolution in Cancer Treatment
In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a type of treatment in which T-cells derived from patient’s blood are modified in laboratory with the addition of a special protein receptor on the T-cells that attack cancer cells. This special receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on patient’s cancer cells. Millions of CAR-T cells are grown in the laboratory and then administered in the patients through infusion. These cells bind to the infected cancer cells and have the ability to kill them thereby leading to curing of the cancer. Masking of cancer cells from immune cells can be combated by the incorporation of immune checkpoint inhibitors in body which can detect and inhibit cancer cells. This innovative approach of using the body’s immune cells to target cancer causing cells has been successful used in the treatment of pediatric relapsed acute lymphoblastic leukemia, refractory non-Hodgkin lymphoma, and other cancers.
The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018 and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).
Figure 1. North America CAR-T Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth, 2018–2028
Source: Coherent Market insights (2018)
Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012 across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada, around 22,340 people in Canada were diagnosed with some form of blood cancer, of which 9,000 cases were lymphoma.
Moreover, development of new and effective therapy options to cure symptoms of the disease is also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to aid in growth of the market over the forecast period.
Furthermore, increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling growth of the market. For instance, in December 2016, the National Cancer Advisory Board authorized US$ 1.8 Bn in funding for Cancer Moonshot, which is an initiative taken up to accelerate research with an aim to make more therapies available to patients with cancer.
However, side effects associated with the cell therapy may lead to cytokine release syndrome (CRS) and other neurological problems that include seizures, coma, hallucinations, and delirium. This factor is expected to hinder the market growth.
In terms of market size, North America is dominant in the global CAR-T cell therapy market. This is attributed to rapid development and launch of new therapies for the treatment of cancer by key players in the market in the region. For instance, in August 2017, the U.S. Food and Drug Administration (FDA) approved Kymriah, a CAR-T cell therapy to treat pediatric and young adult patients suffering with a form of acute lymphoblastic leukemia. Moreover, a large patient pool suffering from cancer in the U.S. and Canada is expected to further support growth of region in the global market. For instance, according to the Centers of Disease Control and Prevention (CDC) 2016, around 171,000 patients with blood cancer are diagnosed each year in the U.S. Europe is expected to be the second most prominent market, in terms of revenue, owing to rising investment and extensive research for development of cancer therapies in the region. For instance, the European Hematology and Oncology department published an undergoing study in 2017 that states the role of CAR-T cells in treatment of Leukapheresis. Furthermore, Asia Pacific is expected to exhibit highest growth over the forecast period, owing to increasing number of global players collaborating and signing research as well as manufacturing contracts for CAR-T cell therapies with local players in the region. For instance, Cesca Therapeutics signed a license agreement with China-based, Boyalife Group, in March 2018, for CAR-T cell related bioprocessing, development, and manufacturing outsourcing.
Market players are engaged in developing and launching innovative products and adopt merger and acquisition strategies to retain position in the global CAR-T cell therapy market
Key players in the market are engaged in extensive research and development to launch new targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19 CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover, key players are focusing on strategic merger and acquisition to enhance their share in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, to develop an investigational CAR-T cell therapy for treating cancer.
Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.
CAR-T cell therapy is a novel immunotherapy that helps to treat various types of cancers. CAR-T cells are genetically engineered cell receptors that are attached to the T-cells of the cancer patients and infused through the blood stream that activates immune system to kill the cancer causing cells in the body. The T-cells injected into the patient’s body aids in reducing the risk of recurrence of tumor and thus, acts as a cure treatment for patients suffering with blood cancer. The CAR-T cell therapy is a solution to overcome the disease progression, identify the cancer causing cells, and kill them using body’s own immune system and defense mechanism.
Market Dynamics
CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.
Key features of the study:
- This report provides in-depth analysis of CAR-T cell therapy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2017 – 2028), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global CAR-T cell therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study includes Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc. and CARsgen Therapeutics, Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing strategies
- The global CAR-T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the CAR-T cell therapy market
Detailed Segmentation:
- Global CAR-T Cell Therapy Market, by Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- Global CAR-T Cell Therapy Market, by Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- Global CAR-T Cell Therapy Market, by Region:
- North America
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- U.S.
- Canada
- Latin America
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Targeted Antigen:
- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1
- Others
- By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis International AG *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Kite Pharma, Inc. (Gilead Sciences, Inc.)
- Juno Therapeutics (Celgene Corporation)
- Bluebird Bio, Inc. (Celgene Corporation)
- Sorrento Therapeutics Inc.
- Mustang Bio, Inc.
- Aurora Biopharma Inc.
- Legend Biotech (Genscript Biotech Corporation)
- Pfizer, Inc.
- CARsgen Therapeutics, Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Targeted Antigen
- Market Snippet By Therapeutic Application
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Industry Trend
- Epidemiology/Prevalence/Incidence
- Merger and Acquisitions
- New Product Approvals/Launch
- Global Car T Cell Therapy Market, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 - 2028
- Segment Trends
- CD 19
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- BCMA
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- HER2
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- GD2
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- CD20
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- CD22
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- CD30
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- CD33
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- HER1
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Global Car T Cell Therapy Market, By Therapeutic Application, 2017 - 2028 (USD Million)
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Acute Lymphocytic Leukemia
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 - 2028
- Chronic Lymphocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Follicular Lymphoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Mantle Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Glioblastoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Sarcoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Neuroblastoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Acute Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Hepatocellular Carcinoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
- Introduction
- Global Car T Cell Therapy Market, By Regions, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Europe
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Asia Pacific
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Latin America
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Africa
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Middle East
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 - 2028
- Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Kite Pharma, Inc. (Gilead Sciences, Inc.)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Juno Therapeutics (Celgene Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Bluebird Bio, Inc. (Celgene Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sorrento Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Mustang Bio, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Aurora Biopharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Legend Biotech (Genscript Biotech Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- CARsgen Therapeutics, Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Novartis International AG
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 90 market data tables and 40 figures on "Car T Cell Therapy Market - Global forecast to 2028”.
Related Insights :
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.